Boston Scientific’s SCS leads linked to 1,081 serious injuries in FDA alert
Boston Scientific recalled its Infinion CX leads, used with SCS systems, due to potential mechanical stress causing injuries. The FDA reported 1,081 serious injuries linked to the issue. Boston Scientific and other medtech companies face lawsuits over SCS system failures. The global neurology devices market, including SCS, is projected to exceed $25bn by 2034, with the North American SCS market valued at $3.5bn by 2033, according to GlobalData.
How this was made
The 30-second read
Why it matters
The recall could accelerate litigation costs and affect future sales of SCS products.
Market read
The alert introduces new risk for Boston Scientific and may influence broader medtech valuations.
What to watch
Potential for insurance recoveries and the ability to replace leads without major disruption.
Background
Boston Scientific faces multiple lawsuits over spinal cord stimulator systems; the FDA alert adds regulatory pressure.
Ticker impact
FDA issued an alert on Boston Scientific's Infinion CX leads, reporting 1,081 serious injuries and a recall recommendation.
Downside pressure as investors assess recall costs and litigation exposure.
Recall of a key product line and ongoing MDL litigation are material adverse events for a large medtech firm.
Market effects
May prompt heightened scrutiny of SCS devices across the medtech sector.
U.S. medtech stocks could see short-term pressure.
Global neuromodulation market outlook may be reassessed.
Counterpoint
If the recall is limited to unused leads, impact on revenue may be modest.
Key entities
- CompanyBoston Scientific
Medical device manufacturer issuing the recall.
- RegulatorFDA
U.S. agency issuing the safety alert.
